MedTrace Logo

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

NCT04648696 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-02-14

Study results available
· View outcomes & findings →

Summary

Evaluate the safety and outcomes associated between the two treatment modalities

Conditions

Interventions

DRUG

Vancomycin CI

The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin

DRUG

Vancomycin II

Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • John Williamson, PharmD · Wake Forest Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2022-10-31
Completion
2022-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648696 on ClinicalTrials.gov